MAS
58
2
DG
6
2
EQT
57
-2
URBN
56
14
XRX
44
3
SWK
64
5
WU
32
2
DE
63
3
PM
62
-2
NWL
53
3
SCHW
62
-2
TDC
80
4
VNO
60
10
WAT
55
2
DRI
53
5
RHI
59
2
BBY
46
10
HST
49
-9
HCP
66
8
KEY
46
3
MAS
58
2
DG
6
2
EQT
57
-2
URBN
56
14
XRX
44
3
SWK
64
5
WU
32
2
DE
63
3
PM
62
-2
NWL
53
3
SCHW
62
-2
TDC
80
4
VNO
60
10
WAT
55
2
DRI
53
5
RHI
59
2
BBY
46
10
HST
49
-9
HCP
66
8
KEY
46
3
Financhill
Back

Structure Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
32

GPCR
Structure Therapeutics

Last Price:
33.44
Seasonality Move:
-14.82%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Structure Therapeutics Price Quote

$33.44
+0.03 (+11.1%)
(Updated: November 23, 2024 at 5:37 AM ET)

Structure Therapeutics Key Stats

Sell
32
Structure Therapeutics (GPCR) is a Sell
Day range:
$29.60 - $34.00
52-week range:
$26.61 - $66.38
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.13%
Volume:
1.2M
Avg. volume:
781.8K
1-year change:
-34.96%
Market cap:
$1.9B
Revenue:
$0
EPS:
$-2.19

How Much Does Structure Therapeutics Make?

Data Unavailable

Is Structure Therapeutics Growing As A Company?

Data Unavailable

Structure Therapeutics Stock Price Performance

What Is Structure Therapeutics 52-Week High & Low?

Structure Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Structure Therapeutics?

Is Structure Therapeutics Cash Flow Positive?

  • What Is GPCR Cash Flow From Operations?
    Cash flow from operations (TTM) is -$101.9M
  • What Is Structure Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $796.3M
  • What Is Structure Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$572.9M

Structure Therapeutics Return On Invested Capital

Data Unavailable

Structure Therapeutics Earnings Date & Stock Price

Structure Therapeutics Competitors

Structure Therapeutics Dividend Yield

Structure Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -7.14%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 85.82
Upside from Last Price: 156.86%

Major Shareholders

  • How many GPCR shares are owned by institutional investors?
    130.6M GPCR shares are owned by institutional investors
  • How many GPCR shares are owned by insiders?
    2.2M GPCR shares are owned by insiders